• Read more about Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-valent Pneumococcal Conjugate Vaccine) in Infants and Children

NEW YORK, N.Y., June 22, 2023 - Pfizer Inc. (NYSE: PFE) announced today that the U.S.

• Read more about Pfizer’s ABRYSVO™ Receives Recommendation for Use in Older Adults from Advisory Committee on Immunization Practices

• ABRYSVO recommended for adults 60 years and older to help protect against Respiratory Syncytial Virus (RSV) disease 
• Pfizer presented initial data from mid- RSV season two in the Northern Hemisphere, which demonstrated ABRYSVO maintained efficacy against RSV-associated lower respiratory tract disease (LRTD)
• Additional data presented by Pfizer supports coadministration of ABRYSVO with flu vaccine in older adults 

NEW YORK, June 22, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S.

• Read more about Pfizer Announces DUAVEE® (conjugated estrogens/bazedoxifene), an Estrogen-Based Menopause Hormone Therapy, Now Back in Stock with Improved Packaging

NEW YORK, June 5, 2023 – Pfizer Inc. (NYSE: PFE) today announced that DUAVEE® (conjugated estrogens/bazedoxifene), an estrogen-based menopause hormone therapy, is now back in stock in the United States, with improved packaging, following a voluntary recall. The recall was due to an issue with the packaging and was not based on any efficacy or safety concerns with the product itself.

• Read more about Ready to Respond: Pfizer’s Zithromax® Program & Covid-19

Hundreds of colleagues at Pfizer and partner manufacturing sites have come together to respond to the sudden and urgent need for Zithromax® around the world. The commitment to excellence and equity have driven a global response to ensure supply of one of Pfizer’s essential medicines.

• Read more about Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

• Read more about Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program

• Phase 1/2 trial will enroll up to 900 healthy U.S.

• Read more about Pfizer Responds to Research Claims

New York, N.Y., January 27, 2023 – Allegations have recently been made related to gain of function and directed evolution research at Pfizer and the company would like to set the record straight.  

• Read more about Pfizer and International Trachoma Initiative Deliver One Billionth Zithromax® Dose Toward Trachoma Elimination by 2030

NEW YORK, January 30, 2023 – Pfizer Inc. (NYSE: PFE) and the International Trachoma Initiative (ITI), a program of the independent nonprofit Task Force for Global Health, today announced the donation of the one billionth Zithromax® (azithromycin) dose as part of the World Health Organization’s (WHO) recommended S.A.F.E. strategy to help prevent and treat trachoma.

• Read more about Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVID™ Conditional Marketing Authorization to Full Marketing Authorization in the European Union

New York, NY, January 27, 2023 – Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended converting the conditional Marketing Authorization (cMA) for PAXLOVID^TM (nirmatrelvir tablets and ritonavir tablets) to standard (also referred to as “full”) Marketing Authorization (MA) for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.

• Read more about Pfizer to Acquire Sanford, North Carolina Manufacturing Site from Abzena